|
Nephrocare Health Services Limited announced its financial results for the second quarter and half year ended 30th September, 2026. The company's Q2 revenue up 23.5% to Rs.303.4 crore. The company reported H1FY27 revenue of Rs. 585.2 crore, up 23.6% YoY, while Adjusted EBITDA grew 15.3% YoY to Rs. 134.4 crore and Adjusted PAT increased 34.7% YoY to Rs. 76.1 crore. During H1FY27, treatments grew 12.6% YoY to 21.01 lakh, while revenue per treatment increased 9.7% YoY to Rs. 2,785. NephroPlus also expanded its network to 570 clinics across six countries, with its entry into Kazakhstan through the acquisition of two clinics in Almaty. The company’s international business now contributes approximately 47% of revenue. Commenting on the Q2 & H1FY27 results, Vikram Vuppala – chairman & MD said, “Dialysis market across the world continues to grow due to the increasing burden of diabetes and hypertension as well as improving access due to various interventions. NephroPlus continues to grow healthily in India and international markets and expect margins to remain in healthy range. We are excited to open NephroPlus in Kazakhstan, which will be our 6th market. The two clinics we acquired are a good starting point for us to better understand the local market nuances before we start scaling this network in Kazakhstan. We have technically qualified in the Saudi Arabia’s Ministry of Health tender. We are one of the 12 Providers who qualified to bid for 4 regions in this tender and hence expect the process to be very competitive."
|